Centocor

Centocor

Biotechnology, , United States, 1001-5000 Employees

centocor.com

  • LinkedIn

Who is CENTOCOR

Subsidiary of Johnson & Johnson, Centocor is a biotechnology company that was founded in Philadelphia in 1979 with an initial goal of developing new diagnostic assays using monoclonal ant...

Read More

map
  • United States Headquarters: United States
  • 1979 Date Founded: 1979
  • 1001-5000 Employees: 1001-5000
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2835 | NAICS Code: 325412 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from CENTOCOR

Centocor Org Chart and Mapping

Employees

Andre Acloque

Product Director, Oncology Marketing

Ilona Rubino

Assistant Director, R&D Communications

Dan Amann

Sr. Validation Engineer

Michael Ursini

Executive Immunology Specialist

Alison Rogers

Associate Scientist II

Cynthia Flynn

Director Cmc Regulatory Affairs

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Centocor

Answer: Centocor's headquarters are located at United States

Answer: Centocor's official website is https://centocor.com

Answer: Centocor's SIC: 2835

Answer: Centocor's NAICS: 325412

Answer: Centocor has 1001-5000 employees

Answer: Centocor is in Biotechnology

Answer: Centocor contact info: Phone number: Website: https://centocor.com

Answer: Subsidiary of Johnson & Johnson, Centocor is a biotechnology company that was founded in Philadelphia in 1979 with an initial goal of developing new diagnostic assays using monoclonal antibody technology. In 1982 Centocor developed their first product approved by the U.S. Food and Drug Administration (FDA) a diagnostic test used to detect the rabies virus, and in that same year transitioned into a publicly traded company. Subsequently, the company moved to a larger facility in Malvern, Pennsylvania (a northwest suburb of Philadelphia). In 1984, Centocor opened an overseas plant in Leiden, the Netherlands. Eighteen years after its foundation, (in 1997), Centocor achieved its first year of operating profitability. In 1998, Centocor divested itself of its diagnostic division and launched its top-selling monoclonal antibody Remicade (infliximab) for its first FDA approved indication in Crohn's Disease. In 1999, Centocor became a wholly owned subsidiary of Johnson & Johnson, the worldwide manufacturer and marketer of healthcare products. Subsequently, Remicade's market has expanded with approvals for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, and pediatric Crohn's disease. Remicade was approved for plaque psoriasis in September 2006. Centocor also markets ReoPro (abciximab), a biologic agent indicated as an adjunct to coronary angioplasty (PTCA). Since being acquired by Johnson and Johnson, Centocor has increased its annual sales from approximately $500 million to more than $2 billion. During the same period, research and development investment increased from $75 million to more than $300 million. In 2004 Centocor purchased a new manufacturing plant in St. Louis, Missouri, and is currently opening a new manufacturing facility in County Cork, Ireland. The Dutch plant has been expanded substantially with a $250 million investment in additional production facilities, which were opened in 2006.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access